"Interferon-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
| Descriptor ID |
D016898
|
| MeSH Number(s) |
D12.644.276.374.440.890.250 D12.776.467.374.440.890.250 D23.529.374.440.890.250
|
| Concept/Terms |
Interferon-alpha- Interferon-alpha
- Interferon alpha
- alpha-Interferon
- alpha Interferon
- Interferon, Lymphoblastoid
- Lymphoblastoid Interferon
- Interferon, Lymphoblast
- Lymphoblast Interferon
- Interferon Alfa
- Interferon, alpha
- Interferon, Leukocyte
- Leukocyte Interferon
Interferon alpha-17- Interferon alpha-17
- Interferon alpha 17
- Interferon alpha-T
- Interferon alpha T
- LeIF I
- Interferon alpha-88
- Interferon alpha 88
Interferon alpha-7- Interferon alpha-7
- Interferon alpha 7
- LeIF J
- Interferon alpha-J
- Interferon alpha J
Interferon alpha-5- Interferon alpha-5
- Interferon alpha 5
- Interferon alpha5
- IFN-alpha5
- IFN alpha5
Interferon alpha-2- Interferon alpha-2
- Interferon alpha 2
- Interferon-alpha 2
- Interferon alpha-A
- Interferon alpha A
- LeIF A
- IFN-alpha 2
- IFN-alpha-2
|
Below are MeSH descriptors whose meaning is more general than "Interferon-alpha".
Below are MeSH descriptors whose meaning is more specific than "Interferon-alpha".
This graph shows the total number of publications written about "Interferon-alpha" by people in this website by year, and whether "Interferon-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 1 | 4 |
| 1996 | 4 | 1 | 5 |
| 1997 | 6 | 1 | 7 |
| 1998 | 6 | 1 | 7 |
| 1999 | 2 | 1 | 3 |
| 2000 | 5 | 1 | 6 |
| 2001 | 6 | 1 | 7 |
| 2002 | 12 | 0 | 12 |
| 2003 | 7 | 2 | 9 |
| 2004 | 4 | 0 | 4 |
| 2005 | 5 | 5 | 10 |
| 2006 | 4 | 2 | 6 |
| 2007 | 6 | 5 | 11 |
| 2008 | 6 | 2 | 8 |
| 2009 | 3 | 0 | 3 |
| 2010 | 4 | 4 | 8 |
| 2011 | 5 | 7 | 12 |
| 2012 | 5 | 2 | 7 |
| 2013 | 9 | 0 | 9 |
| 2014 | 7 | 4 | 11 |
| 2015 | 7 | 1 | 8 |
| 2016 | 2 | 1 | 3 |
| 2017 | 6 | 2 | 8 |
| 2018 | 4 | 3 | 7 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 2 | 3 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon-alpha" by people in Profiles.
-
Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon a gene therapy in a murine bladder cancer model. Front Immunol. 2024; 15:1387229.
-
IFN-treated macrophage-derived exosomes prevents HBV-HCC migration and invasion via regulating miR-106b-3p/PCGF3/PI3K/AKT signaling axis. Front Cell Infect Microbiol. 2024; 14:1421195.
-
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-a in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024 06 13; 143(24):2490-2503.
-
Moving toward disease modification in polycythemia vera. Blood. 2023 11 30; 142(22):1859-1870.
-
Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval. Front Immunol. 2023; 14:1260498.
-
Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ~40% of patients. J Exp Med. 2023 09 04; 220(9).
-
Adenoviral gene therapy for bladder cancer. Cell. 2023 03 02; 186(5):893.
-
Long term study of topical interferon a-2b eye drops as primary treatment of ocular surface squamous neoplasia. Ocul Surf. 2023 04; 28:108-114.
-
Clinical and In Vitro Evidence Favoring Immunoglobulin Treatment of a Chronic Norovirus Infection in a Patient With Common Variable Immunodeficiency. J Infect Dis. 2022 11 11; 226(10):1781-1789.
-
Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy. Blood Adv. 2022 10 11; 6(19):5546-5549.